ANDA 88295, held by Hospira. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 88295 (Lidocaine Hydrochloride Preservative Free), held by Hospira, was first approved by FDA on May 16, 1984, with 8 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE 4% Lidocaine Hydrochloride Injection is indicated for the production of topical anesthesia of the mucous membranes of the respiratory tract or the genito-urinary tract. It may be injected trans-tracheally to anesthetize the larynx and trachea, and it may be administered by retrobulbar injection to provide anesthesia for ophthalmic surgery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 16, 1984 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride Preservative Free4% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Aug 27, 2021 | Supplement 24Labeling · Standard review | Approved | None posted |
| Apr 16, 2010 | Supplement 15Labeling | Approved | None posted |
| Oct 3, 1996 | Supplement 8Manufacturing | Approved | None posted |
| Sep 28, 1993 | Supplement 6Labeling | Approved | None posted |
| Jun 29, 1989 | Supplement 4Labeling | Approved | None posted |
| Dec 23, 1988 | Supplement 3Labeling | Approved | None posted |
| Aug 1, 1986 | Supplement 2Manufacturing | Approved | None posted |
| Apr 18, 1985 | Supplement 1Manufacturing | Approved | None posted |
| May 16, 1984 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters